Payment overview · 2025
General Payments
$435.04
23 reported records · 14 companies
Healthcare provider profile · identity verified
Mark Hameed Stephen, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STERLING HEIGHTS, MI · NPI 1356555916
Verified facts
What the public records show
CMS Open Payments records show Mark Hameed Stephen, M.D. received $435.04 in general payments during 2025 across 23 reported records.
Amgen Inc. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.17 | 15.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.51 | 14.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.18 | 9.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $38.93 | 8.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $35.55 | 8.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.47 | 7.0% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $30.06 | 6.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.80 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.03 | 4.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.73 | 4.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.71 | 4.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.44 | 3.5% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $15.30 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.16 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $435.04 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.13 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.18 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.18 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $38.93 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $35.55 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 148 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 601 | 137 |
| Lisinopril | Lisinopril | 326 | 68 |
| Furosemide | Furosemide | 316 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 296 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 67 |
| Losartan Potassium | Losartan Potassium | 250 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 56 |
| Metformin Hcl | Metformin Hcl | 233 | 52 |
| Alprazolam | Alprazolam | 230 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 62 |
| Tramadol Hcl | Tramadol Hcl | 217 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 42 |
| Omeprazole | Omeprazole | 206 | 44 |
| Simvastatin | Simvastatin | 187 | 48 |
| Sertraline Hcl | Sertraline Hcl | 180 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 168 | 25 |
| Potassium Chloride | Potassium Chloride | 161 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 52 |
| Eliquis | Apixaban | 148 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 26 |
| Carvedilol | Carvedilol | 135 | 34 |
| Famotidine | Famotidine | 135 | 22 |
| Ibuprofen | Ibuprofen | 133 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 34 |
| Gabapentin | Gabapentin | 126 | 33 |
| Azithromycin | Azithromycin | 118 | 87 |
| Lorazepam | Lorazepam | 113 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 37 |
| Prednisone | Prednisone | 104 | 65 |
| Allopurinol | Allopurinol | 92 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 22 |
| Donepezil Hcl | Donepezil Hcl | 90 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 84 | 58 |
| Metformin Hcl Er | Metformin Hcl | 74 | 21 |
| Atenolol | Atenolol | 73 | 19 |
| Januvia | Sitagliptin Phosphate | 71 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | suppressed |
| Cephalexin | Cephalexin | 65 | 46 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 16 |
| Jardiance | Empagliflozin | 64 | 20 |
| Finasteride | Finasteride | 63 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 22 |
| Trazodone Hcl | Trazodone Hcl | 55 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 11 |
| Meloxicam | Meloxicam | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 13 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Nifedipine Er | Nifedipine | 42 | 12 |
| Ozempic | Semaglutide | 42 | 11 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Risperidone | Risperidone | 41 | suppressed |
| Nystop | Nystatin | 38 | 16 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 34 | suppressed |
| Bumetanide | Bumetanide | 34 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | 12 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 15 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 13 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Novolog | Insulin Aspart | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $435.04 · 23 records | Amgen Inc. | CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EOHILIA, EVENITY, GARDASIL 9, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, Rystiggo, UBRELVY, WATCHMAN FLX, Wegovy, XIFAXAN, ZENPEP | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error